Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the fourth quarter of 2023.
- Eton Pharmaceuticals reported earnings per share of -9 cents. This was below the analyst estimate for EPS of -4 cents.
- The company reported revenue of $7.31 million.
- This was 5.03% worse than the analyst estimate for revenue of $7.70 million.